Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion

Are You Looking for a High-Growth Dividend Stock?

Are You Looking for a High-Growth Dividend Stock?

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

AstraZeneca PLC's (LON:AZN) Stock Is Going Strong: Have Financials A Role To Play?

AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout

20 Countries with the Highest Age Dependency Ratio in the World

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

What Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), AstraZeneca (AZN)

AstraZeneca’s Ultomiris Approval Spurs Buy Rating Amid Growth in Rare Disease Segment

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts